

iDose-QUALIFIED MEDICATIONS FOR PK-INFORMED TDM DOSING DECISION SUPPORT

iDose CAPABILITY	iDose GEN3	iDose®GEN7.0.0
Infliximab (Intravenous, IV)	✓	✓
Infliximab (Subcutaneous, SC)	✗	✓
Adalimumab, SC	✗	✓
Vedolizumab, IV	✗	✓
Vedolizumab, SC	✗	✓
Ustekinumab, IV	✗	✓
Ustekinumab, SC	✗	✓
Golimumab, IV	✗	✓
Golimumab, SC	✗	✓
Guselkumab, IV	✗	✓
Guselkumab, SC	✗	✓
Risankizumab, IV	✗	✓
Risankizumab, SC	✗	✓
Mirikizumab, IV	✗	✓
Mirikizumab, SC	✗	✓
Certolizumab SC *To be released soon	✗	✓
Etanercept SC *To be released soon	✗	✓
Secukinumab SC *To be released soon	✗	✓

iDose-QUALIFIED INDICATIONS FOR PK-INFORMED TDM DOSING DECISION SUPPORT

iDose CAPABILITY	iDose GEN3	iDose®GEN7.0.0
Crohn’s Disease	✓	✓
Ulcerative Colitis	✓	✓
Rheumatoid Arthritis	✗	✓
Ankylosing Spondylitis	✗	✓
Psoriatic Arthritis	✗	✓
Juvenile Idiopathic Arthritis	✗	✓
Polyarticular juvenile idiopathic arthritis	✗	✓
Systemic juvenile idiopathic arthritis	✗	✓
Psoriasis	✗	✓
Atopic Dermatitis	✗	✓
Hidradenitis suppurivativa	✗	✓
Uveitis	✗	✓
Multiple Sclerosis	✗	✓
Asthma	✗	✓
Cryopyrin	✗	✓
Giant Cell Arteritis	✗	✓
Systemic Sclerosis associated interstitial lung disease	✗	✓

iDose ADDITIONAL DECISION SUPPORT TOOLS FOR ULCERATIVE COLITIS AND CROHN’S DISEASE PK-INFORMED TDM DOSING

iDose CAPABILITY	iDose GEN3	iDose®GEN7.0.0
Probability of Anti-Drug-Antibody Occurrence at the present time	✗	✓
Probability of C-Reactive Protein (CRP) Normalization at the present time	✗	✓
Probability of Mucosal Healing at the present time	✗	✓

iDose EASE OF USE

iDose CAPABILITY	iDose GEN3	iDose®GEN7.0.0
Improved Numerical Entry	✗	✓
EHR/EMR Ready	✗	✓

